Are you Dr. Tozbikian?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 34 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
410 W 10th Ave E419
Columbus, OH 43210Phone+1 614-293-5905Fax+1 614-293-4715
Summary
- Dr. Gary Tozbikian, MD is a board certified pathologist in Columbus, Ohio. He is currently licensed to practice medicine in Ohio and Pennsylvania. He is affiliated with The OSUCCC - James and Ohio State University Wexner Medical Center.
Education & Training
University of Pennsylvania Health System GI/Hepatic PathologyFellowship, Selective Pathology, 2011 - 2012- University of Pennsylvania Health SystemResidency, Pathology-Anatomic and Clinical, 2007 - 2011
Ohio State University College of MedicineClass of 2007
Certifications & Licensure
OH State Medical License 2013 - 2025
PA State Medical License 2007 - 2012- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
Publications & Presentations
PubMed
- Cold ischemia time and formalin fixation time in endometrial cancer: Should breast cancer guidelines for preanalytical variables be applied to hysterectomy specimens?Paulina J Haight, Sydney Lammers, Quinn Kistenfeger, Chelsea Leipold, Adrian A Suarez
Gynecologic Oncology. 2024-12-01 - Clinicopathologic Characteristics and Follow-Up Outcomes of Invasive Breast Carcinoma With Different Positive HER2 Fluorescence In Situ Hybridization Patterns: Experie...Zaibo Li, Yan Hu, Dan Jones, Weiqiang Zhao, Gary Tozbikian
Modern Pathology. 2024-10-26 - 1 citationsBest practices for achieving consensus in HER2-low expression in breast cancer: current perspectives from practising pathologists.Gary Tozbikian, Marilyn M Bui, David G Hicks, Shabnam Jaffer, Thaer Khoury
Histopathology. 2024-09-01
Press Mentions
PD-L1 Testing in Triple-Negative Breast Cancer: Post Hoc IMpassion130 Substudy Evaluates PD-L1 IHC Assay PerformanceApril 1st, 2020
